ImmunityBio Revenue Surges 700% Driven by Anktiva Commercial Success

ImmunityBio (IBRX) is experiencing a transformative period following the successful commercial launch of its immunotherapy platform, Anktiva. The company reported a staggering 700% year-over-year increase in revenue for fiscal year 2025, reaching approximately $113 million. This growth is primarily driven by the FDA approval of Anktiva for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Investors are now closely monitoring upcoming clinical trial readouts for bladder cancer and glioblastoma, which serve as potential catalysts for further expansion. While the company's valuation remains at a premium, the shift toward chemo-free oncology solutions provides a strong competitive edge. Analysts suggest that the positive clinical momentum and massive revenue surge solidify the company's position in the biotech sector.